Avenue Therapeutics Announces First Patient Dosed In Phase 1b/2a Clinical Trial Of AJ201 For The Treatment Of Spinal And Bulbar Muscular Atrophy
Portfolio Pulse from Happy Mohamed
Avenue Therapeutics, Inc. (NASDAQ:ATXI) has announced that the first patient has been dosed in the Phase 1b/2a clinical trial of AJ201 for the treatment of spinal and bulbar muscular atrophy (SBMA). AJ201 is currently the lead drug candidate in the clinic for SBMA and enrollment in the trial is expected to be complete by the end of 2023 or early 2024 with potential topline data in 2024. The trial aims to demonstrate how AJ201's novel, multi-fold mechanism of action reduces accumulation of mutant AR aggregates to potentially decrease neuroinflammation, protect cells from oxidative stress, and ultimately, improve clinical outcomes for SBMA patients.
July 27, 2023 | 12:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Avenue Therapeutics has started the Phase 1b/2a clinical trial of AJ201 for the treatment of SBMA. This could potentially lead to a new treatment option for SBMA, which currently has no approved treatments. The results of the trial could have a significant impact on the company's stock.
The initiation of the clinical trial is a significant step for Avenue Therapeutics. If the trial is successful, it could lead to the approval of a new treatment for SBMA, which currently has no approved treatments. This could potentially increase the company's revenues and positively impact the stock price. However, the results of the trial are not expected until 2024, so the impact on the stock price may not be immediate.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100